While the pharma/biotech sector was not spared COVID-19 pain this year, with various companies hit hard by disruptions in clinical studies and delays in elective surgeries and in individuals seeking medical care, the authors of today’s article note that “some biotech stocks have more than doubled during this period, especially those focusing on developing a coronavirus vaccine.” They proceed to look at “six biotech/drug stocks that have managed to perform well so far this year backed by their encouraging progress in developing a coronavirus vaccine.” For more, CLICK HERE.
